Cytokinetics Inc (CYTK) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.

Total Assets Chart for Cytokinetics Inc

Cytokinetics Inc (CYTK) total assets for FY2025 were USD 1.4B, a 1.6% change from FY2024. Cytokinetics Inc's total assets grew from USD 61.0M in 2000 to USD 1.4B in 2025 (2233.9% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 21.7%, 10-year CAGR of 28.6%, 20-year CAGR of 14.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$8.53B
Implied Share Price
$61.35
Enterprise Value
$9.26B
Revenue (TTM)
$67.67M
EBITDA
-$695.36M
Profit Margin
0.00%
Trailing P/E
—
Forward P/E
117.65
Price/Book (MRQ)
60.31
Price/Sales (TTM)
126.04
EV/EBITDA
-15.82
EV/Revenue
145.20
Dividend Yield
—
Book Value
$-1.25
Free Cash Flow (FY2025)
-$534.82M
Free Cash Flow Yield
-6.27%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.